双联抗血小板治疗预治疗对急性缺血性卒中静脉溶栓的影响
这项前瞻性多中心研究在790例静脉溶栓的急性缺血性卒中患者中比较双联抗血小板预治疗(DAPP)者与未接受者的结局。DAPP与无症状颅内出血风险升高相关,但与3个月良好功能结局可能性更高相关;倾向性评分匹配后两组安全性和有效性结局无差异。作者认为DAPP不应成为不进行静脉溶栓的理由。
要点
- DAPP+组与DAPP-组症状性颅内出血发生率相似(3.4% vs 3.2%)。
- 多变量分析中DAPP与无症状颅内出血风险升高相关(OR=3.53)。
- DAPP不应作为符合条件者不进行静脉溶栓的理由。
核心结论
- DAPP与静脉溶栓后症状性颅内出血率和3个月死亡率升高无关。
- DAPP不应作为符合其他条件的急性缺血性卒中患者不进行静脉溶栓的理由。
- 本研究提供III级证据表明DAPP与症状性颅内出血风险显著升高无关,但研究缺乏排除症状性颅内出血出血风险有潜在意义增加的精确度。
研究设计与样本
- 前瞻性多中心研究,比较DAPP+与DAPP-的静脉溶栓治疗急性缺血性卒中患者,并在倾向性评分匹配前后比较结局。
- 共纳入790例静脉溶栓患者,其中58例(7%)卒中前使用DAPP(平均年龄68±13岁;57%为男性;美国国立卫生研究院卒中量表评分中位数8分)。
主要发现
- DAPP+患者较DAPP-患者年龄更大且危险因素更多。
- 症状性颅内出血发生率两组相似(3.4% vs 3.2%)。
- 多变量分析中,DAPP与无症状颅内出血风险升高相关(OR=3.53,95%CI 1.47-8.47;p=0.005),也与3个月良好功能结局可能性更高相关(OR=2.41,95%CI 1.06-5.46;p=0.035)。
- 倾向性评分匹配后,41例DAPP+患者与82例DAPP-患者匹配,两组基线特征及安全性和有效性结局均无差异。
临床怎么用
- DAPP不应作为符合其他条件的急性缺血性卒中患者不进行静脉溶栓的理由。
局限性
- 本研究缺乏排除症状性颅内出血出血风险有潜在意义增加的精确度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We sought to determine the safety and efficacy of IV thrombolysis (IVT) in acute ischemic stroke (AIS) patients with a history of dual antiplatelet therapy pretreatment (DAPP) in a prospective multicenter study. METHODS: We compared the following outcomes between DAPP+ and DAPP- IVT-treated patients before and after propensity score matching (PSM): symptomatic intracranial hemorrhage (sICH), asymptomatic intracranial hemorrhage, favorable functional outcome (modified Rankin Scale score 0-1), and 3-month mortality. RESULTS: Among 790 IVT patients, 58 (7%) were on DAPP before stroke (mean age 68 ± 13 years; 57% men; median NIH Stroke Scale score 8). DAPP+ patients were older with more risk factors compared to DAPP- patients. The rates of sICH were similar between groups (3.4% vs 3.2%). In multivariable analyses adjusting for potential confounders, DAPP was associated with higher odds of asymptomatic intracranial hemorrhage (odds ratio = 3.53, 95% confidence interval: 1.47-8.47; p = 0.005) but also with a higher likelihood of 3-month favorable functional outcome (odds ratio = 2.41, 95% confidence interval: 1.06-5.46; p = 0.035). After propensity score matching, 41 DAPP+ patients were matched to 82 DAPP- patients. The 2 groups did not differ in any of the baseline characteristics or safety and efficacy outcomes. CONCLUSIONS: DAPP is not associated with higher rates of sICH and 3-month mortality following IVT. DAPP should not be used as a reason to withhold IVT in otherwise eligible AIS candidates. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for IVT-treated patients with AIS, DAPP is not associated with a significantly higher risk of sICH. The study lacked the precision to exclude a potentially meaningful increase in sICH bleeding risk.
引用
- Tsivgoulis G, Goyal N, Kerro A, et al. Dual antiplatelet therapy pretreatment in IV thrombolysis for acute ischemic stroke. Neurology. 2018. PMID: 30120131. doi:10.1212/WNL.0000000000006168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。